Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Evidence Full-length TB-4 has human clinical research across corneal, cardiac, and wound-repair programs, including clean Phase 1 safety data, plus dermal wound-healing models
Continuous standalone KPV alongside GLOW produces the same four-peptide composition with more handling
No human trial dose exists Every dose number above comes from rodent studies scaled to a human size or from research community use
Based on investigational protocol reports and the clinical trial data, most subjects begin to see measurable changes in body composition at 4 to 6 weeks on a consistent daily protocol at 300 mcg
Our 5-Amino-1MQ results and benefits guide takes a closer look at reported timelines, before-and-after claims, and the gaps in human evidence
These animals are fed a high-fat diet until they become obese, then randomized to receive either 5-amino-1mq or a control treatment
